Drug Profile
DSTA 4637S
Alternative Names: Anti-S. aureus TAC - Genentech; DSTA4637S; RG-7861; Sym-009Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Symphogen
- Developer Genentech
- Class Antibacterials; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Staphylococcal infections
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 28 Jan 2022 No recent reports of development identified for phase-I development in Staphylococcal-infections(Treatment-experienced) in South Korea (IV, Infusion)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Staphylococcal-infections(Treatment-experienced) in Spain (IV, Infusion)